I.M. Sechenov First Moscow State Medical University

sechenov.ru

Total trials

132

Active

24

Phase 3

1

Total enrollment

39,310

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Longidaza1
Metronidazole 500 mg1
Rifaximin1
Standart medical treatment1

Next readouts

  • 2025-06-01
  • 2026-06
  • 2026-09-30

Top conditions

  • Coronary Artery Disease6
  • Heart Failure6
  • COVID-195
  • Prostate Cancer5
  • Quality of Life4
  • Arterial Hypertension4
  • Soft Tissue Atrophy4
  • Prostate Adenocarcinoma4

Frequently asked questions about I.M. Sechenov First Moscow State Medical University

How many clinical trials does I.M. Sechenov First Moscow State Medical University have on ClinicalTrials.gov?
I.M. Sechenov First Moscow State Medical University is listed as the lead sponsor on 132 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of I.M. Sechenov First Moscow State Medical University's trials are in Phase 3?
1 of I.M. Sechenov First Moscow State Medical University's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does I.M. Sechenov First Moscow State Medical University focus on?
I.M. Sechenov First Moscow State Medical University's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Heart Failure, COVID-19, Prostate Cancer, Quality of Life.
When are I.M. Sechenov First Moscow State Medical University's next clinical trial readouts?
I.M. Sechenov First Moscow State Medical University has 3 upcoming primary-completion readouts tracked here; the soonest is “Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age”, expected around 2025-06-01.